Compare McCormick & Company, Incorporated (MKC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Spyre Therapeutics Inc. Common Stock — how do they compare? McCormick & Company, Incorporated trades at $44.93 (market cap $12.02B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: McCormick & Company, Incorporated is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 4.3% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 68 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MKC | SYRE | |
|---|---|---|
Market Cap | $12.02B | $7.52B |
Volume | 3,822,006 | 1,441,031 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $108.92 |
52-Week Low | $44.14 | $22.18 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $16.71B | $6.52B |
Dividend Yield | 4.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $44.80, down 1.71% on the day, with a bearish technical signal from moving averages. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Valuation ratios appear attractive with a P/E of 8.07 and net income margin of 19.39%. Recent news highlights the acquisition of McCormick de Mexico and a reaffirmed 2026 outlook.
The stock offers value with solid profitability and dividend growth, but faces near-term technical headwinds and mixed analyst sentiment. Upside exists toward the $53.50 consensus target, though execution risks and market volatility require monitoring. The current price near support at $44 suggests a potential entry point for long-term investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
